LB PHARMACEUTICALS INC

LBRX

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Baker Bros. Advisors RA Capital Management Commodore Capital

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management8.7%Feb 17, 2026

SC 13GRA Capital Management7.5%Sep 19, 2025

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 200,000Value: $4.5M

## Signal Note: Baker Bros. Initiates Position in LB Pharmaceuticals (LBRX) **Note: The reported position value of ~$4.45B on 200,000 shares implies a per-share price of ~$22,260, which appears to be a data error — likely a misreported share count or valuation artifact. This should be verified before acting on the signal.** That said, a new Baker Bros. position in LBRX is noteworthy given their track record of high-conviction, concentrated bets in clinical-stage biotech. LBRX's lead asset is **LB-102**, an oral muscarinic M1/M4 agonist in development for **schizophrenia**, which reported positive Phase 1b data and is advancing toward a Phase 2 trial — a space Baker has historically targeted ahead of pivotal catalysts. Even if the true

RA Capital ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CTNM3 funds SYRE3 funds NUVL3 funds TYRA3 funds ALKS2 funds FDMT2 funds BCRX2 funds CLDX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: RA Capital Initiates $49.2M Position in LB Pharmaceuticals RA Capital's entry into LBRX suggests conviction in the company's clinical pipeline, likely tied to LB's lead program in a high-value indication—most probable being azeliragon (TTP488) for early Alzheimer's disease, which has shown mixed Phase 2 results but remains in development. The $49.2M stake (representing ~2.2M shares) signals confidence in near-term catalysts, potentially including upcoming clinical readouts, regulatory interactions, or partnering activity that could de-risk the pipeline. Timing and position size warrant monitoring of upcoming 8-K filings and quarterly updates for specific inflection points.